Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ICU Medical (ICUI)

ICU Medical Q4 revenue rose to $629.8 million; GAAP net loss widened to $23.8 million

Mixed Impact 3 of 5 earnings Written later

ICU Medical reported fourth quarter 2024 revenue of $629.8 million, up from $587.9 million a year earlier, and adjusted diluted EPS of $2.11 versus $1.57. GAAP net loss widened to $23.8 million, or $(0.97) per share, from $17.1 million, or $(0.71) per share, a year earlier. The company also gave fiscal 2025 guidance for GAAP net loss of $(45) million to $(28) million and adjusted EPS of $6.55 to $7.25, excluding a pending IV Solutions joint venture.

Key points

  • Q4 2024 revenue was $629.8 million, versus $587.9 million in Q4 2023; GAAP gross margin was 36.1%, versus 29.2%.
  • Q4 2024 adjusted EBITDA was $105.5 million, versus $86.3 million; GAAP net loss was $(23.8) million, or $(0.97) per diluted share.
  • FY2025 guidance: GAAP net loss of $(45) million to $(28) million; adjusted EBITDA of $395 million to $425 million, excluding the IV Solutions joint venture.
  • The IV Solutions joint venture is expected to close in Q2 2025 and, if so, reduce 2025 adjusted EBITDA guidance by $15 million to $20 million.

The filing

CompanyICU Medical (ICUI)
Form8-K, current report
Filed with the SECFeb 27, 2025, 4:10 PM ET
Accession number0000883984-25-000006

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:01 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.